Domestic bio-风投企业 are achieving major milestones in rapid succession, including 国内外 技术转让s for innovative new drug 管线s and international 联合研究 initiatives.
The fact that many of these companies are still early-stage 初创企业s receiving government support makes this all the more significant, reaffirming the potential of 'K-BIO' even in challenging 国内外 industry conditions.
In addition, RudaCure recently transferred its 角膜溃疡 and 角膜损伤 treatment technology to 翰林制药, and Owl Bio entered a strategic partnership with Kyungdong 制药 to commercialize long-acting injectable drugs.
These bio 初创企业s are participants in the 中小企业部' 'Innovative Field 初创企业 Package Support' program, sharing the common thread of successfully commercializing their technologies with the backing of government strategic 初创企业 support. Since 2020, the ministry has been selecting and systematically supporting promising 初创企业s recognized for their core technological capabilities and growth potential in the three major new industry sectors: system semiconductors, bio-health, and future mobility — with continuous and systematic 研发 and commercialization support.
A representative from the 韩国毒性研究所, which supports bio-health companies, noted, "Given the nature of the bio sector where most 初创企业s are technology-based, the reality is that most companies face greater difficulties in the commercialization stage after founding," adding, "In this context, the ability to quickly bring innovative technologies to market using government commercialization support as a catalyst has been the key to achieving early results."
K-BIO Ventures Equipped with Technological Prowess Score Big Day After Day: Herald Economy